Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers
- 22 January 2020
- Vol. 126 (8), 1651-1655
- https://doi.org/10.1002/cncr.32715
Abstract
Background With the increasing use of multigene panel tests, pathogenic and likely pathogenic (P/LP) variants are identified more frequently in the moderate‐penetrance breast cancer genes ATM and CHEK2. Lifetime breast cancer risk among women with P/LP variants in these genes generally exceeds 20%, meeting the threshold at which high‐risk breast cancer screening through breast magnetic resonance imaging (MRI) is recommended. Methods Among a registry‐based sample of 56 ATM and 69 CHEK2 carriers, the authors sought to determine the percentage of relatives in whom a P/LP variant would impact breast cancer surveillance. Lifetime breast cancer risks for unaffected, female first‐degree and second‐degree relatives were estimated using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA). Results Among first‐degree relatives of ATM and CHEK2 carriers, only 22.6% and 14.9%, respectively, were found to have lifetime breast cancer risks of ≥20% based on family cancer history alone; however, when including the proband's P/LP variant in the model, these percentages increased significantly to 56.6% and 55.3%, respectively (P < .0001 and P < .0001, respectively). Similar increases in lifetime breast cancer risks were found among second‐degree relatives. Conclusions The results of the current study suggest that the majority of female first‐degree and second‐degree relatives of ATM and CHEK2 carriers do not qualify for breast MRI based on family cancer history alone. Therefore, testing for these genes, as well as awareness of positive moderate‐penetrance breast cancer gene results in the family, may impact MRI eligibility. These findings highlight the potential usefulness of and need for breast cancer risk models that incorporate moderate‐penetrance gene positivity to inform screening recommendations among at‐risk family members.Keywords
Funding Information
- National Cancer Institute (U54 CA163072)
This publication has 19 references indexed in Scilit:
- Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast CancerAnnals of Surgical Oncology, 2015
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panelCancer, 2014
- Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United StatesISRN Oncology, 2013
- Educational Needs and Preferred Methods of Learning Among Florida Practitioners Who Order Genetic Testing for Hereditary Breast and Ovarian CancerJournal of Cancer Education, 2013
- Rare variants in the ATMgene and risk of breast cancerBreast Cancer Research, 2011
- CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 ControlsJournal of Clinical Oncology, 2008
- Population-based estimates of breast cancer risks associated withATMgene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family RegistryHuman Mutation, 2006
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002
- Ataxia-Telangiectasia: Identification and Detection of Founder-Effect Mutations in the ATM Gene in Ethnic PopulationsAmerican Journal of Human Genetics, 1998
- A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 KinaseScience, 1995